Partnerships and Relationships
Our business model focuses on building a diversified portfolio of late-stage drugs, primarily in the field of oncology, through acquisition and partnerships, rather than through in-house drug discovery.
We then bring those drugs through the development process, and make them available to patients, worldwide, through our in-house commercial sales organization.
We establish strategic alliances with leading biotechnology and pharmaceutical companies, represented by the list below, to leverage their strengths, mitigate risk inherent in the drug development process, accelerate drug development timelines, and generate cash through milestones, royalties and ultimately direct sales.
Partnering for Success
Spectrum recently formed the following strategic partnerships:
Spectrum Pharmaceuticals Signs a Strategic Partnership With Servier Canada
Spectrum Pharmaceuticals Divests Rights to ZEVALIN® (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Eagle Pharmaceuticals and Spectrum Pharmaceuticals Announce Co-Promotion Agreement
Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs.
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-enabledTM Melphalan. Product candidate is being investigated as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma
Hanmi Pharmaceutical Co., Ltd.
Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting G-CSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals
Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN®. Irrevocable License From Bayer Healthcare Leverages Spectrum's Existing Clinical, Regulatory and Marketing Investments